HRB Open Res · Aug 21, 2026
Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study
By Peters N, Haritgan D, Williams S et al.
Background: Prostate cancer is the most common solid tumour amongst men in Ireland with a median age at diagnosis of 67 years. The incidence of frailty amongst cancer patients is high. Among patients undergoing systemic anti-cancer therapy, frailty increases the risk of treatment related toxicity, hospitalisation, and death and is associated with a poorer quality of life. The prevalence of frailty amongst men and its impact on function, quality of life and patient outcomes has not previously been described. Aims This study aims to describe the demographic, clinical, socioeconomic and frailty characteristics of men living with prostate in the Mid-West of Ireland. This study will also assess the predictive accuracy of three frailty screening tools used in Irish clinical practice for predicting adverse outcomes at 6 and 12 months. Methods Patients with a diagnosis of prostate cancer and aged >65 years attending the Mid-Western Cancer Centre will have three screening tools (G8, CFS, PRISMA 7) performed by face-to-face interview with a research nurse (RN) during their index visit. The RN will complete a baseline demographic questionnaire, baseline functional status and record baseline comorbidities. A telephone follow up will occur at six and twelve months and will capture healthcare utilisation as well as outcome data including treatment toxicity, unscheduled attendance to the hospital, hospital/hospice admission and death. Longitudinal changes in functional status, quality of life, and healthcare utilisation over the 12-month follow-up period will be assessed using appropriate statistical tests. Associations between frailty status and adverse clinical outcomes will be explored using univariable and multivariable regression analyses. Implications The findings of this study will provide important real-world insights into frailty, treatment practices, and patient-centred outcomes in prostate cancer, and may help inform future screening strategies and intervention studies.